# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
MYC-directed epigenomic controller exerts anti-tumor effect in preclinical models of EGFR inhibitor-resistant NSCLC regardles...
Piper Sandler analyst Edward Tenthoff reiterates Omega Therapeutics (NASDAQ:OMGA) with a Overweight and lowers the price tar...
Chardan Capital analyst Keay Nakae maintains Omega Therapeutics (NASDAQ:OMGA) with a Buy and lowers the price target from $1...
Omega Therapeutics (NASDAQ:OMGA) reported quarterly losses of $(0.37) per share which beat the analyst consensus estimate of $(...
Shares of Applied Therapeutics, Inc.
U.S. stocks traded mixed toward the end of trading, with the Dow Jones index gaining over 100 points on Thursday. The Dow trad...